Luana Guimaraes de Sousa MD
Department of Thoracic-Head & Neck Med Onc, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Assistant Professor, Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Assistant Professor, Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2012 | Federal University of Bahia, Salvador, BR, Medical Doctor |
Postgraduate Training
| 2020-2022 | Clinical Fellowship, Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2015-2018 | Clinical Fellowship, Medical Oncologist, Sao Paulo University, Sao Paulo |
| 2013-2015 | Clinical Residency, Internal Medicine, State University of Campinas (UNICAMP), Campinas |
Licenses & Certifications
| 2025 | Texas Medical Board Medical License |
| 2024 | Texas Medical Oncology Board Faculty Temporary License |
| 2024 | Advanced Cardiac Life Support (ACLS) |
| 2023 | Texas Medical Board |
| 2022 | Texas Medical Board |
| 2020 | United States Medical Licensing Examination (USMLE) Certificated |
Experience & Service
Faculty Academic Appointments
Oncology Attending, Thoracic/Head and Neck Medical Oncology, Sao Paulo University, Sao Paulo, 2018 - 2020
Administrative Appointments/Responsibilities
Elected Faculty Senate, The University of Texas MD Anderson Cancer Center, Houston, TX, 2023 - 2025
Extramural Institutional Committee Activities
Member, Institutional Review Board (IRB), The University of Texas MD Anderson Cancer Center, 2026 - Present
Faculty representative, Faculty Senate, The University of Texas MD Anderson Cancer Center, 2023 - 2025
Honors & Awards
| 2025 - Present | Awarded (ITT) trial protocol “A phase II study of Zanzalitinib for Patients with Recurrent or Metastatic Olfactory Neuroblastoma”, Exelixis (United States) |
| 2025 - 2027 | Early-Career Clinical and Translational Research Group Prize, UT MD Anderson |
| 2024 - Present | Cemiplimab and cetuximab prior salvage surgery in patients with recurrent oral cavity squamous cell carcinoma (OCSCC), Regeneron (United States) |
| 2024 - 2026 | Prioritizing Research Innovation and Mentoring (PRIME) Excellence Award, UT MD Anderson |
| 2022 - Present | Pilot Grant in support of "Oral Cavity Carcinoma Immune Microenvironment and its Impact on Clinical Outcome", american head and neck socie |
| 2022 - Present | Endowed Fellowship Award |
| 2022 - 2024 | ASCO Young Investigator Award, Conquer Cancer Foundation |
| 2022 | MD Anderson Cancer Center Endowed Fellowship Award, MD Anderson Cancer Center |
| 2010 | Water Colin Award, Brazilian Society of Protozoology and Immunology |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2026. Neoadjuvant IO era: Where are we?. Invited. Multidisciplinary Head and Neck Cancer Research Working Retreat. Houston, Texas, US.
- 2025. Role of Systemic therapy in Head and Neck Cancers. Invited. Oral oncology Symposium. Houston, Texas, US.
- 2024. Potential Systemic Approaches in Anaplastic Thyroid Carcinoma: Focusing on ADCs. Invited. MD Anderson Anaplastic Thyroid Retreat. Houston, Texas, US.
- 2023. Advancements in Salivary Gland Cancer Treatment: Current Strategies and Future Directions. Heme/Onc Grand Rounds, US.
Regional Presentations
- 2024. Immune Checkpoint Inhibitor Therapy for Periocular Squamous Cell Carcinoma with Perineural Spread to the Orbit and Skull Base. Conference. American Society of Ophthalmic Plastic and Reconstructive Surgery (ASOPRS 2024). Houston, Texas, US.
National Presentations
- 2025. Nasopharyngeal Carcinoma - Induction vs Concurrent vs Adjuvant: When and Why?. Invited. 2025 Combined Otolaryngology Spring Meeting. New Orleans, Louisiana, US.
- 2024. Adjuvant pembrolizumab after multimodal therapy for anaplastic thyroid cancer. Conference. American Thyroid Association Annual Meeting, US.
- 2024. Novel Therapies in Salivary Gland Cancers. Invited. 3rd Hawaii Summit on Thoracic Oncology, Hawaii, US.
- 2024. Tisotumab Vedotin in Head and Neck Cancers. Invited. 3rd Hawaii Summit on Thoracic Oncology, Hawaii, US.
- 2018. Glottic cancer with cartilage invasion: what is the best approach Oral presentation. Invited, BR.
International Presentations
- 2023. Oral Presentation at the 7th World Congress of the International Federation of Head and Neck Oncologic Societies Natural history of lung metastasis and the prognostic value of its doubling time in patients with adenoid cystic carcinoma. Conference. Oral Presentation at the 7th World Congress of the International Federation of Head and Neck Oncologic Societies Natural history of lung metastasis and the prognostic value of its doubling time in patients with adenoid cystic carcinoma. Rome, IT.
Formal Peers
- 2023. Combined Therapy for Head & Neck Cancer. Visiting. Houston, TX, US.
- 2023. Systemic therapy for Skin Cancers. Visiting, US.
- 2023. Treatment for recurrent/metastatic Head and neck squamous cell. Visiting, US.
- 2018. Head and Neck Cancers: Optimizing Patient Selection For Definitive Chemoradiation. Visiting. Sao Paulo, Sao Paulo, BR.
- 2018. Head and Neck Cancers: Management of Definitive Therapy Side Effects. Visiting. sao paulo, sao paulo, BR.
Grant & Contract Support
| Date: | 2025 - 2027 |
| Title: | Early-Career Clinical and Translational Research Group (EC-CTRG) in support of the Project Entitled "Mapping Immunologic and Molecular Changes Across Neoadjuvant Cetuximab and Cemiplimab Treatment" |
| Funding Source: | MDACC |
| Role: | PI |
| Date: | 2024 - 2027 |
| Title: | Prioritizing Research Innovation & Mentoring Excellence (PRIME) Award |
| Funding Source: | University of Texas MD Anderson Cancer Center |
| Role: | PI |
| Date: | 2022 - Present |
| Title: | Conquer Young Investigator Award to support project entitled "Landscape of the immune microenvironment in HPV-related oropharynx squamous cell carcinoma and its impact on outcomes following chemoradiotherapy (CRT)” |
| Funding Source: | American Society of Clinical Oncology (ASCO) |
| Role: | PI |
| ID: | AWD00006614 |
| Date: | 2022 - Present |
| Title: | The American Head and Neck Society Pilot Grant in Support of Oral Cavity Carcinoma Immune Microenvironment and its Impact on Clinical Outcome |
| Funding Source: | American Head and Neck Society |
| Role: | PI |
| ID: | FP00015648 |
| Date: | 2009 - 2010 |
| Title: | Novel antiretroviral therapy impact in multi resistant HIV patients |
| Funding Source: | Institutional Program of Scientific Initiation (PIBIC) |
| Role: | Co-I |
| Date: | 2009 - 2010 |
| Title: | Genetic modulation by leishmania braziliensis infection |
| Funding Source: | Institutional Program of Scientific Initiation (PIBIC) |
| Role: | Co-I |
Selected Publications
Peer-Reviewed Articles
- Townes TG, Martinez J, Gross ND, Li G, Goepfert R, Myers J, Sikora AG, Choi K, Hutcheson KA, Wenye Song MD, Lee A, Moran A, Lewis CM, Akhave N, Johnson F, De Sousa LG, Maniakas A, Wang JR, Su SY, Lai SY, Hanna E, Zhao X, Lango MN. A Standardized Algorithm's Impact on Primary Detection in Head and Neck Carcinoma of Unknown Primary. Otolaryngol Head Neck Surg, 2026. e-Pub 2026.
- Hoff CO, Heeke S, Mitani Y, de Sousa LG, Siqueira JM, Li K, Bonini F, Bell D, Marques-Piubelli ML, Lin S, Wargo JA, El-Naggar AK, McGrail DJ, Ferrarotto R. Axitinib plus Avelumab in Recurrent/Metastatic Adenoid Cystic Carcinoma: Biomarker Analysis and Updated Results of the Phase II Trial. Clinical Cancer Research, 2026. e-Pub 2026.
- Hamidi S, Vodopivec D, Busaidy N, Gule-Monroe M, Akhave N, Banuchi V, Ferrarotto R, Fournier I, Gunn B, Iyer P, Lee A, Maniakas A, Vicente, Marczyk R, Ning M, Sousa LD, Spiotto M, Waguespack SG, Wang JR, Zafereo ME, Cabanillas M, Dadu R. Real-world Experience with Lenvatinib plus Pembrolizumab in Metastatic BRAF Wild-type Anaplastic Thyroid Carcinoma. Thyroid, 2026. e-Pub 2026.
- Sousa LG, Bates JE, Anand P, Caudell JJ, Colevas A, Runge C, Sharon JD, Awan M, Beadle BM, Choe JH, Gidley PW, Harari PM, Henson C, Katzel JA, Lee NY, McDowell L, Mell LK, Nader M, Rudra S, Wang K, Yang G, Yom SS, Wise-Draper TM. Cisplatin During Radiation for Head and Neck Cancer: Insights from NRG Oncology Experience. Journal of the National Cancer Institute, 2025. e-Pub 2025.
- Siqueira JM, Heguedusch D, Cunha MT, Sousa LG, Marques-Piubelli ML, Carvalho GL, Hoff CO, Bonini F, Mitani Y, Spiotto MT, Goepfert R, Nunes FD, Matos LL, Kowalski LP, McGrail DJ, El-Naggar AK, Ferrarotto R. Exploring TROP2 expression in oropharyngeal squamous cell carcinoma: Association with prognosis and tumor immune microenvironment composition. Oral Oncol 169:107634, 2025. e-Pub 2025. PMID: 40865331.
- Siqueira JM, Mitani Y, Marques-Piubelli ML, Hoff CO, Bonini F, Sousa LG, Mitani M, Carvalho GL, Nunes FD, Matos LL, Lin SY, Spiotto MT, Hanna EY, McGrail DJ, El-Naggar AK, Ferrarotto R. TROP2 Expression in Salivary Gland Adenoid Cystic Carcinoma (ACC) According to Histologic Subtype: Therapeutic Implications. J Oral Pathol Med 54(8):658-666, 2025. e-Pub 2025. PMID: 40624990.
- Cabanillas ME, Busaidy NL, Gunn G, Iyer PC, Ferrarotto R, Gule-Monroe M, Maniakas A, Williams MD, Liu S, Fellman B, Spiotto M, Hamidi S, Akhave N, Lee A, Wang JR, Sousa LG, Marczyk VR, Zafereo M, Dadu R. Adjuvant pembrolizumab after upfront multimodal therapy for stage IVB Anaplastic Thyroid Cancer, 2025. e-Pub 2025.
- Hamidi S, Maniakas A, Akhave NS, Banuchi VE, Busaidy NL, Dadu R, Ferrarotto R, Guise TA, Hofmann M, Hosseini S, Hu MI, Iyer PC, Mansour M, Marczyk VR, Roy-Chowdhuri S, Sherman SI, Sousa LG, Wang JR, Williams MD, Zafereo ME, Waguespack SG, Cabanillas ME. Characterization of advanced RAS-driven follicular-derived thyroid cancers and review of future therapeutic avenues. The Journal of Clinical Endocrinology & Metabolism, 2025. e-Pub 2025.
- Hoff CO, Feng L, Bonini F, Sousa LG, Wang K, Siqueira JM, Nguyen Q, El-Naggar AK, Hofstetter WL, Sepesi B, Ferrarotto R. Survival outcomes of pulmonary metastasis‐directed local therapy in adenoid cystic carcinoma. Cancer, 2025. e-Pub 2025.
- Lu TJ, Fan J, Guimaraes de Sousa L, Sagiv O, Hernandez S, Bolanos Gomez L, Akhave N, Ferrarotto R, Esmaeli B. PD-1 Inhibitors for Periocular Squamous Cell Carcinoma With Perineural Spread to the Orbit and Skull Base. Ophthalmic Plast Reconstr Surg, 2025. e-Pub 2025. PMID: 40237556.
- Hoff CO, Sousa LG, Bonini F, Lago ED, Wang K, Siqueira JM, Mitani Y, El-Naggar AK, Ferrarotto R. Clinical Outcomes With Notch Inhibitors in Notch-Activated Recurrent/Metastatic Adenoid Cystic Carcinoma. Cancer Medicine 14(5):e70663, 2025. e-Pub 2025. PMID: 40025676.
- Hamidi S, Dadu R, Zafereo ME, Ferrarotto R, Wang JR, Maniakas A, Gunn GB, Lee A, Spiotto MT, Iyer PC, Sousa LG, Akhave NS, Ahmed S, Learned KO, Lu C, Lai SY, Williams M, Hosseini SM, Busaidy NL, Cabanillas ME. Initial Management of BRAF V600E-Variant Anaplastic Thyroid Cancer: The FAST Multidisciplinary Group Consensus Statement. JAMA Oncol 10(9):1264-1271, 2024. e-Pub 2024. PMID: 38990526.
- Esmaeli B, Fan J, Goldberg H, Lu T, Gross ND, Akhave N, Sousa LG, Ferrarotto R. Immune checkpoint inhibitors with or without chemotherapy for orbital, conjunctival, and ocular adnexal squamous cell carcinoma. Can J Ophthalmol, 2024. e-Pub 2024. PMID: 39043259.
- Hoff CO, Lago EAD, Sousa LG. First Use of AXL Targeting in Metastatic, Refractory, Adenoid Cystic Carcinoma: A Case Report, 2024. e-Pub 2024. PMID: 38579194.
- Dal Lago EA, Sousa LG, Yang Z, Hoff CO, Bonini F, Sawyer M, Wang K, Lewis W, Wahid KA, Hanna EY, El-Naggar A, Fuller CD, Kundu S, Godoy M, Ferrarotto R. Prognostic value of tumor volume doubling time in lung-metastatic adenoid cystic carcinoma. Oral Oncology 151, 2024. e-Pub 2024. PMID: 38507991.
- Goldfarb J, Fan J, Sousa LG, Akhave N, Myers J, Goepfert R, Manisundaram K, Zhao J, Frank SJ, Moreno A, Ferrarotto R, Esmaeli B. Neoadjuvant Chemotherapy Alone or Combined with EGFR-Directed Targeted Therapy or Anti-PD-1 Immunotherapy for Locally Advanced Lacrimal Sac and Nasolacrimal Duct Carcinomas. Semin Ophthalmol:1-7, 2024. e-Pub 2024. PMID: 38500295.
- Sousa LG, Liu S, Bhosale P, Altan M, Darbonne W, Schulze K, Dervin S, Yun C, Mahvash A, Verma A, Futreal A, Gite S, Cuentas EP, Cho WC, Wistuba I, Yao JC, Woodman SE, Halperin DM, Ferrarotto R. Atezolizumab plus bevacizumab in advanced Merkel cell carcinoma: A prospective study. Oral Oncology 151, 2024. e-Pub 2024. PMID: 38460288.
- Heeke S, Gay CM, Estecio MR, Tran H, Morris BB, Zhang B, Tang X, Raso MG, Rocha P, Lai S, Arriola E, Hofman P, Hofman V, Kopparapu P, Lovly CM, Concannon K, Sousa LG, Lewis WE, Kondo K, Hu X, Tanimoto A, Vokes NI, Nilsson MB, Stewart A, Jansen M, Horváth I, Gaga M, Panagoulias V, Raviv Y, Frumkin D, Wasserstrom A, Shuali A, Schnabel CA, Xi Y, Diao L, Wang Q, Zhang J, Van Loo P, Wang J, Wistuba II, Byers LA, Heymach JV. Tumor-and circulating-free DNA methylation identifies clinically relevant small cell lung cancer subtypes. Cancer Cell 42(2):225-237.e5, 2024. e-Pub 2024. PMID: 38278149.
- Sewastjanow-Silva M, Cabanillas ME, Dal Lago EA, Cunha MT, Zafereo M, MD, FACS, El-Naggar AK, Ferrarotto R, Elamin YY, Sousa LG. Sustained Response to Lorlatinib and Pemetrexed in ALK Fusion–Positive Anaplastic Thyroid Carcinoma with Multiple Distant Metastases: A Case Report, 2024. e-Pub 2024.
- Juliana Mota Siqueira, Yoshitsugu Mitani, Sousa LG, Camilla O Hoff, Flavia Bonini. Analysis of B7-H4 Expression Across Salivary Gland Carcinomas Reveals Adenoid Cystic Carcinoma–Specific Prognostic Relevance. Modern Pathology 37(1), 2024. e-Pub 2024. PMID: 38015043.
- Sousa LG, McGrail DJ, Neto FL, Li K, Marques-Piubelli ML, Ferri-Borgogno S, Dai H, Mitani Y, Burr NS, Cooper Z, Kinneer K, Cortez MA, Lin S, Bell D, Naggar AE, Burks JK, Ferrarotto R. Spatial Immunoprofiling of Adenoid Cystic Carcinoma Reveals B7-H4 Is a Therapeutic Target for Aggressive Tumors. Clinical Cancer Research 29(16):3162-3171, 2023. e-Pub 2023. PMID: 37256648.
- Ferrarotto R, Sousa LG, Feng L, Mott FE, Blumenschein GR, Altan M, Bell D, Bonini F, Li K, Marques-Piubelli ML, Dal Lago EA, Johnson JJ, Mitani Y, Godoy M, Lee A, Kupferman ME, Hanna EY, Glisson BS, Elamin YY, El-Naggar AK. Phase II Clinical Trial of Axitinib and Avelumab in Patients With Recurrent/Metastatic Adenoid Cystic Carcinoma. Journal of Clinical Oncology 41(15):2843-2851, 2023. e-Pub 2023. PMID: 36898078.
- Sousa LG, Neto FL, Dal Lago EA, Sikora AG, Hanna EY, Moreno AC, Phan J, Glisson BS, Bell D, Ferrarotto R. Human papillomavirus status and prognosis of oropharyngeal high-grade neuroendocrine carcinoma. Oral Oncology 138, 2023. e-Pub 2023. PMID: 36702015.
- Sousa LG, Jovanovic K, Ferrarotto R. Metastatic Adenoid Cystic Carcinoma: Genomic Landscape and Emerging Treatments. Current treatment options in oncology 23(8):1135-1150, 2022. e-Pub 2022. PMID: 35854180.
- Neto FL, Sousa LG, Lewis WE, Glisson BS, Heymach JV, Tsao A, Ferrarotto R. Outcomes of Critically Ill Lung Cancer Patients Initiating Targeted Therapy or Immunotherapy in the Intensive Care Unit. Journal of Intensive Care Medicine 37(8):1055-1059, 2022. e-Pub 2022. PMID: 34787022.
- Sousa LG, McGrail DJ, Li K, Marques-Piubelli ML, Gonzalez C, Dai H, Ferri-Borgogno S, Godoy M, Burks JK, Lin S, Bell D, Ferrarotto R. Spontaneous tumor regression following COVID-19 vaccination. Journal for immunotherapy of cancer 10(3), 2022. e-Pub 2022. PMID: 35241495.
- Sousa LG, Rajapakshe K, Rodriguez Canales J, Chin R, Feng L, Wang Q, Barrese T, Massarelli E, William WN, Johnson FM, Ferrarotto R, Wistuba II, Coarfa C, Lee JJ, Wang J, Melief CJ, Curran M, Glisson BS. ISA101 and nivolumab for HPV-16 + cancer. Journal for immunotherapy of cancer 10(2), 2022. e-Pub 2022. PMID: 35193933.
- Sousa LG, Wang K, Torman DK, Binks BJ, Rubin ML, Andersen C, Lewis WE, Rivera MJ, Kaya D, El-Naggar AK, Hanna EY, Esmaeli B, Frank SJ, Bell D, Glisson BS, Rodon Ahnert J, Meric-Bernstam F, Lee JJ, Ferrarotto R. Treatment patterns and outcomes of palliative systemic therapy in patients with salivary duct carcinoma and adenocarcinoma, not otherwise specified. Cancer 128(3):509-518, 2022. e-Pub 2022. PMID: 34661906.
- Sousa LG, Neto FL, Torman DK, Diaz Jr EM, Rosenthal D, Glisson BS, Bell D, Ferrarotto R. Therapeutic approaches and outcomes in patients with larynx or hypopharynx high-grade neuroendocrine carcinoma. Head and Neck 43(12):3788-3795, 2021. e-Pub 2021. PMID: 34524729.
- Ferrarotto R, Sousa LG, Qing Y, Kaya D, Stephen B, Jain D, Bell D, Pant S, Tsimberidou AM, Janku F, Blumenschein GR, Glisson BS, Rodon Ahnert J, Piha-Paul SA, Lee JJ, Wong MK, Lu C, Meric-Bernstam F, Naing A. Pembrolizumab in Patients with Refractory Cutaneous Squamous Cell Carcinoma. Advances in Therapy 38(8):4581-4591, 2021. e-Pub 2021. PMID: 34241781.
- Sousa LG, Ferrarotto R. Pembrolizumab in the first-line treatment of advanced head and neck cancer. Expert review of anticancer therapy 21(12):1321-1331, 2021. e-Pub 2021. PMID: 34689660.
- Mota JM, Sousa LG, Braghiroli MI, Siqueira LT, Neto JB, ChapChap P, De Oliveira Hoff AA, Hoff P. Pembrolizumab for metastatic adrenocortical carcinoma with high mutational burden Two case reports. Medicine (United States) 97(52), 2018. e-Pub 2018. PMID: 30593126.
- Sousa R, Andrade VM, Bair T, Ettinger NA, Sousa LG, Andrade L, Guimarães LH, Machado PR, Carvalho EM, Wilson ME, Schriefer A. Early suppression of macrophage gene expression by Leishmania braziliensis. Frontiers in Microbiology 9(OCT), 2018. e-Pub 2018. PMID: 30374342.
Review Articles
- Naara S, Ferrarotto R, Sousa L, Akhave N, Gunn B, Phan J, Su SY, Raza SM, DeMonte F, Hann E. Induction therapy in advanced sinonasal cancers: outcomes, selection, and preservation. Academia Oncology 3(3), 2026. e-Pub 2026.
- Bonini F, Sousa LG, Ferrarotto R. New and emerging drugs for the treatment of advanced cutaneous squamous cell carcinoma. Expert Opinion on Emerging Drugs 28(2):97-106, 2023. e-Pub 2023. PMID: 37144289.
- Sousa LG, Neto FL, Lin J, Ferrarotto R. Treatment of Recurrent or Metastatic Adenoid Cystic Carcinoma. Current oncology reports 24(5):621-631, 2022. e-Pub 2022. PMID: 35212920.
- Mota JM, Sousa LG, Riechelmann R. Complications from carcinoid syndrome. ecancermedicalscience 10, 2016. e-Pub 2016. PMID: 27594907.
Editorials
- Sousa LG, Ferrarotto R. B7-H4: A potential therapeutic target in adenoid cystic carcinoma. Oncotarget 15:807-808, 2024. PMID: 39576662.
Abstracts
- Amit M, Saddawi-Konefka R, Naara S, Akhave N, de Sousa LG, Netto F, Jindal S, Akhter S, Xie T, Vu Y, Allison JP, Myers J, Chambers MS, Kadara H, Sharma P. Intralesional PD-1 blockade for oral cancer prevention: First-in-class phase 1 trial. ASCO Meeting 2026, 2026. e-Pub 2026.
- de Sousa LG, Akhave N, Du R, Le X, Moreno AC, Morris VK, Ferrarotto R, Myers J, Gillison ML, Lee J. Circulating HPV DNA for early detection of minimal residual disease after definitive therapy in oropharyngeal cancer: A phase II biomarker-driven study. ASCO meeting 2026, 2026. e-Pub 2026.
- de Sousa LG, Williams MD, Dong W, Lee A, Learned KO, Gross ND, Ferrarotto R. Neoadjuvant cemiplimab plus cetuximab prior to salvage surgery for recurrent oral cavity squamous cell carcinoma. ASCO meeting 2026, 2026. e-Pub 2026.
- Tan HN, Mirallas O, Selvadurai P, Wotman M, Sousa L, Akhave N, Sanber K, Ferrarotto R, Blumenschein GR, Gillison ML, Johnson FM, Yap TA. The PER3-RORB axis defines a tumor-suppressive circadian state associated with improved survival in head and neck squamous cell carcinoma. American Association For Cancer Research, 2026. e-Pub 2026.
- Tan HN, Wotman M, Sousa L, Sanber K, Akhave N, Blumenschein G, Ferrarotto R, Gillison M, Johnson F, Yap TA. Replication stress coupled to cGAS–STING activation defines an innate immune–inflamed transcriptional state in head and neck squamous cell carcinoma that Is enriched for HPV-positive disease, 2026. e-Pub 2026.
- Amit M, Ferrarotto R, Nagarajan P, Li G, Yuan Y, Morrison W, Rosenthal D, Sousa L, Johnson F, Diaz E, Gidley P, Lewis C, Myers J, Gross N. 1659P Updated pathologic responses from a pilot phase II trial of neoadjuvant immunotherapy for stage II-IV resectable cutaneous squamous cell carcinoma of the head and neck (CSCC-HN). ESMO 2025, 2025. e-Pub 2025.
- Heeke S, Hoff CO, Sousa L, Feng L, Bonini F, Mitani Y, El-Naggar A, Ferrarotto R. 1407P Using liquid biopsies to classify adenoid cystic carcinoma into clinically relevant subtypes. ESMO 2025, 2025. e-Pub 2025.
- Cunha MT, Flynt L, Sewastjanow-Silva M, Wang K, Phan J, Chen M, Sousa L, Akhave N, Williams MD, Hanna EY, Su SY, Ferrarotto R. Outcomes with 177 lutetium-dotatate (177Lu-dotatate) in olfactory neuroblastoma (ONB): A case series. American Society of Clinical Oncology, 2025. e-Pub 2025.
- Siqueira JM, Mitani Y, Marques-Piubelli ML, de Sousa LG, Carvalho GL, Nunes FD, Ferrarotto R. Exploring TROP2 expression as a potential therapeutic target in adenoid cystic carcinoma of the salivary glands. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2025. e-Pub 2025.
- Wang J, Dadu R, Zafereo M, Maniakas A, Hamidi S, Busaidy N, Ferrarotto R, Sousa L, Banuchi V, Gunn B, Spiotto M, Akhave N, Cabanillas ME. 462TiP GRASSROOT: Global real-world data in patients with advanced thyroid cancer on standard of care and specialized interventions - Registry of oncologic outcomes with testing and treatment. Annals of Oncology, 2024. e-Pub 2024.
- Hoff CO, Feng L, Bonini F, Sousa L, Garden A, Ferrarotto R. Day of the week of chemotherapy (CT) during concurrent chemoradiation (CRT) for oropharyngeal squamous cell carcinoma (OPSCC). ESMO, 2024. e-Pub 2024.
- Naara S, Yaniv D, Andrews C, Sathishkumar H, de Sousa LG, Akhave N, Williams MD, Myers J, Chambers MS, Amit M. Intralesional nivolumab in oral potentially malignant disorders: A phase 1 pilot study on safety, tolerability, and preliminary efficacy. 2024 American Society of Clinical Oncology Annual Meeting, 2024. e-Pub 2024.
- Hoff CO, McGrail D, Mitani Y, Heeke S, Sousa L, Santos E, Siqueira JM, Li K, Bell D, Marques-Piubelli ML, Lin S, El-Naggar AK, Ferrarotto R. Axitinib plus avelumab for recurrent/metastatic adenoid cystic carcinoma (R/M ACC): Biomarker analysis of the phase II trial. 2024 ASCO Meeting, 2024. e-Pub 2024.
- Wotman M, Hoff CO, Bonini F, Sawyer M, Wang K, Dal Lago EA, de Sousa LG, Ferrarotto R. Efficacy of cytotoxic chemotherapy in recurrent/metastatic adenoid cystic carcinoma (ACC). 2024 American Society of Clinical Oncology Annual Meeting, 2024. e-Pub 2024.
- de Sousa LG, Siqueira JM, McGrail D, Marques-Piubelli M, Neto FL, Borgogno SF, Nunes FD, Matos L, Kowalski LP, Hoff CO, Dai H, Mitani Y, Li K, Williams MD, Lin S, El-Naggar AK, Sikora AG, Burks J, Gillison ML, Ferrarotto R. The immunological milieu of oropharyngeal squamous cell carcinoma (OPC) according to HPV and smoking status and its influence on prognosis. American Society of Clinical Oncology Annual Meeting, 2024. e-Pub 2024.
- Esmaeli B, Fan J, Goldberg H, Lu T, Akhave N, de Sousa LG, Ferrarotto R. Immunotherapy for local/regional control of locally advanced orbital and periocular squamous cell carcinoma. 2024 American Society of Clinical Oncology Annual Meeting, 2024. e-Pub 2024.
- Lu Tracey, Luana Guimaraes de Sousa, Maria Cabanillas. Checkpoint Inhibitor Therapy for Periocular Squamous Cell Carcinoma with Perineural Spread to the Orbit and Skull Base. ASOPRS 2024 Spring Scientific Symposium, 2024. e-Pub 2024.
- Hoff CO, Feng L, Bonini F, Sousa LG, Wang K, Siqueira JM, Purushothaman A, Nguyen QN, El-Naggar AK, Mehran R, Ferrarotto R. Survival Outcomes following Pulmonary Metastasis-Directed Local Therapy (PM-LT) Relative to No Metastasis-Directed Intervention in Adenoid Cystic Carcinoma (ACC). 2024 Multidisciplinary Head and Neck Cancers Symposium 118(5):e79-e80, 2024. e-Pub 2024.
- Sousa LG, Lago E, Yang Z, Hoff CO, Bonini F, Sawyer M, Wang K, Lewis W, Wahid KA, Hanna EY, El-Naggar AK, Fuller CD, Kundu S, Godoy M, Ferrarotto R. Prognostic Value of Time To Progression vs. Tumor Volume Doubling Time in Patients with Adenoid Cystic Carcinoma Metastatic To The Lung. 2024 Multidisciplinary Head and Neck Cancers Symposium 118(5):e80-e81, 2024. e-Pub 2024.
- Mota Siqueira J, Mitani Y, Hoff C, Bonini F, Sousa LG, Marques-Piubelli M, Purushothaman A, Mitani M, Dai H, Lin SY, Spiotto M, Hanna EY, McGrail D, El-Naggar A, Ferrarotto R. Analysis of B7-H4 Expression Across Salivary Gland Carcinomas Reveals Adenoid Cystic Carcinoma Specific Prognostic Relevance, 2023. e-Pub 2023.
- Hoff CO, Sousa LG, Dal Lago E, Wang K, Mota Siqueira J, Cortez MA, Mitani Y, Purushothaman A, El-Naggar A, Ferrarotto R. 908P Efficacy of NOTCH inhibitors (Ni) relative to prior systemic therapy or observation in patients (pts) with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) . Annals of Oncology 34 (2023): S577-S578. DOI 10.1016/j.annonc.2023.09.2053. Annals of Oncology, 2023. e-Pub 2023.
- Hoff CO, McGrail D, Heeke S, Sousa LG, Li K, Bell D, Mitani Y, Marques-Piubelli, ML, Cortez MA, Lin, Shiaw-Yih, Elamin YY, El-Naggar A, Ferrarotto R. Predictive biomarkers of benefit to axitinib plus avelumab in patients with recurrent/metastatic adenoid cystic carcinoma (R/M ACC). Journal of Clinical Oncology 41 (16_suppl)(6096-6096), 2023. e-Pub 2023.
- Heeke S, Gay CM, Estecio MR, Stewart A, Tran H, Zhang B, Tang X, Raso G, Concannon K, Sousa LG, Lewis WE, Nilsson M, Xi Y, Diao L, Wang Q, Zhang J, Wang J, Wistuba II, Byers LA, Heymach JV. Use of DNA methylation from tumor and plasma to identify four major small cell lung cancer subtypes with distinct biology and therapeutic vulnerabilities. Cancer Research 82(12_supplement):3473-3473, 2022. e-Pub 2022.
- Ferrarotto R, Bell D, Feng L, Li K, Mott F, Blumenschein GR, Sousa LG, Altan M, Marques-Piubelli ML, Dal Lago EA, Kaya D, Godoy M, Kupferman ME, Glisson BS, El-Naggar AK, Elamin YY. A phase 2 clinical trial of axitinib and avelumab in patients with recurrent/metastatic adenoid cystic carcinoma (ACC). Journal of Clinical Oncology 40(16_suppl):6019-6019, 2022. e-Pub 2022.
- Sousa LG, Neto FL, McGrail DJ, Li K, Marques-Piubelli ML, Borgogno SF, Dai H, Mitani Y, Lin S, El-Naggar AK, Bell D, Burks J, Ferrarotto R. Single-cell immune mapping of adenoid cystic carcinoma (ACC) reveals potential therapeutic targets for the aggressive solid subtype. Journal of Clinical Oncology 40(16_suppl):6090-6090, 2022. e-Pub 2022.
- Heeke S, Gay CM, Estecio MR, Stewart A, Tran H, Zhang B, Tang X, Raso MG, Concannon K, Sousa LG, Lewis WE, Kondo K, Nilsson MB, Xi Y, Diao L, Wang Q, Zhang J, Wang J, Wistuba II, Byers LA, JV. MA01.03 Exploiting DNA Methylation for Classification of SCLC Subtypes from Liquid Biopsies Using a Robust Machine Learning Approach. Journal of Thoracic Oncology 17(9):S43, 2022. e-Pub 2022.
- Sousa LG, Lazar F, Torman D, Li K, Sikora A, Moreno A, Hanna E, Phan J, Glisson B, Bell D, Ferrarotto R. High-grade neuroendocrine carcinoma of the oropharynx: A rare entity with prognosis unaffected by HPV. Cancer Research 81(13_Supplement):770, 2021. e-Pub 2021.
- Sousa LG, Wang K, Torman D, Binks B, Andersen C, Lewis WE, Rivera M, Kaya D, El-Naggar AK, Hanna EY, Esmaeli B, Frank SJ, Bell D, Glisson BS, Ahnert JR, Meric-Bernstam F, Lee J, Ferrarotto R. Treatment patterns and systemic therapy outcomes for patients with salivary duct carcinoma and adenocarcinoma NOS. American Society of Clinical Oncology, 2021. e-Pub 2021.
- Neto FL, Sousa LG, Johnson FM, Lee J, Frank SJ, Moreno AC, Dahlstrom K, Ferrarotto R. Comparative assessment of the eighth and seventh AJCC staging edition prognostic performance of patients with p16 positive oropharynx cancer. Journal of Clinical Oncology 39(15_supplement):6067, 2021. e-Pub 2021.
- Lopes AD, Batista DN, Luana Guimaraes de Sousa, Dornellas AFL. First Results of a Brazilian Never or Light Smoker Non-Small Cell Lung Cancer Cohort: epidemiology and Molecular Data. XXI Brazilian Society of Oncology Meeting, 2019. e-Pub 2019.
- Pereira JCB, Fernandes M, Luana Guimaraes de Sousa. Approach in Elderly patients with Locally Advanced Head and Neck Squamous Cell Carcinoma. XX Brazilian Society of Oncology Meeting, 2017. e-Pub 2017.
Book Chapters
- Sousa LG. Manual de Condutas em Oncologia. In: Manual de Condutas em Oncologia. 3. Editora Atheneu, 2018.
- Sousa LG. Clinical Oncology, Therapy Based on Evidences. Hospital Sirio Libanês. In: Oncologia Clinica: Terapia Baseada em Evidencias. Editora Tropical, 2017.
- Sousa LG, Ferrarotto R, Moreno A, Goepfert R. Head and Neck Cancer. In: The MD Anderson Manual of Medical Oncology. 5th. McGraw Hill.
- Sousa LG. Tratado De Oncologia. In: Tratado de Oncologia. 2. Atheneu.
Patient Reviews
CV information above last modified September 15, 2026